دورية أكاديمية
أعرض في EDS

Polyclonal F(ab') 2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency.

التفاصيل البيبلوغرافية
العنوان: Polyclonal F(ab') 2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency.
المؤلفون: Cunha LER; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Stolet AA; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Strauch MA; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Pereira VAR; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Dumard CH; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Gomes AMO; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Monteiro FL; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Higa LM; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Souza PNC; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Fonseca JG; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Pontes FE; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Meirelles LGR; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Albuquerque JWM; Vital Brazil Institute, Niterói, RJ 24230-410, Brazil., Sacramento CQ; Immunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Fintelman-Rodrigues N; Immunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Lima TM; Cell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil., Alvim RGF; Cell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil., Marsili FF; Cell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil., Caldeira MM; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Zingali RB; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., de Oliveira GAP; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Souza TML; Immunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ 21040-900, Brazil., Silva AS; Laboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Muller R; Animal Experimentation Laboratory (LAEAN), Institute of Technology in Immunobiologicals, Bio-Manguinhos, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Rodrigues DDRF; Laboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Jesus da Costa L; Department of Virology, Laboratory of Genetics and Immunology of Viral Infections, Institute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ CEP 21941902 , Brazil., Alves ADR; Laboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Pinto MA; Laboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Oliveira AC; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Guedes HLM; Immunopharmacology Laboratory, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-902, Brazil.; Immunobiotechnology Laboratory, Institute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-902, Brazil.; Interdisciplinary Medical Research Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil., Tanuri A; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil., Castilho LR; Cell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil., Silva JL; Institute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.; National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
المصدر: IScience [iScience] 2021 Nov 19; Vol. 24 (11), pp. 103315. Date of Electronic Publication: 2021 Oct 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:10 6 , and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT 90 ). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab') 2 preparation with PRNT 90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab') 2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab') 2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab') 2 preparation for the clinical treatment of COVID patients.
Competing Interests: The authors declare no competing interest.
(© 2021 The Author(s).)
References: Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
Nat Med. 2020 Aug;26(8):1193-1195. (PMID: 32504052)
Viral Immunol. 2007 Sep;20(3):495-502. (PMID: 17931120)
Nat Struct Mol Biol. 2020 Sep;27(9):846-854. (PMID: 32661423)
PLoS One. 2019 Feb 11;14(2):e0211896. (PMID: 30742635)
Acta Pharmacol Sin. 2005 Dec;26(12):1479-84. (PMID: 16297347)
N Engl J Med. 2021 Feb 18;384(7):610-618. (PMID: 33406353)
Sci Rep. 2021 May 10;11(1):9825. (PMID: 33972631)
Cell. 2021 May 27;184(11):2939-2954.e9. (PMID: 33852911)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Emerg Infect Dis. 2021 May;27(5):1446-1453. (PMID: 33797393)
Cell. 2021 Feb 18;184(4):861-880. (PMID: 33497610)
Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645)
Sci Adv. 2021 Mar 19;7(12):. (PMID: 33608249)
Nature. 2021 Apr;592(7854):438-443. (PMID: 33690265)
Int Immunopharmacol. 2007 Mar;7(3):392-400. (PMID: 17276898)
Medicina (B Aires). 2020;80 Suppl 3:1-6. (PMID: 32658841)
Vaccine. 2016 Feb 24;34(9):1152-61. (PMID: 26802604)
Nature. 2020 Aug;584(7821):450-456. (PMID: 32698192)
Antib Ther. 2020 Nov 24;3(4):246-256. (PMID: 33912795)
Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674)
EClinicalMedicine. 2021 Apr;34:100843. (PMID: 33870149)
J Virol. 2021 Mar 1;95(10):. (PMID: 33649194)
Antiviral Res. 2017 Jan;137:125-130. (PMID: 27890674)
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. (PMID: 33887205)
Science. 2021 May 21;372(6544):815-821. (PMID: 33853970)
Toxicon. 2013 Dec 15;76:63-76. (PMID: 24055551)
Sci Rep. 2017 Feb 03;7:41537. (PMID: 28155869)
Science. 2021 Jun 4;372(6546):1108-1112. (PMID: 33947773)
Inflamm Allergy Drug Targets. 2011 Oct;10(5):369-80. (PMID: 21745181)
Vaccine. 2009 Feb 11;27(7):1067-72. (PMID: 19100805)
Lancet Infect Dis. 2015 Mar;15(3):285-92. (PMID: 25662592)
Sci Rep. 2016 Apr 12;6:24179. (PMID: 27067649)
Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960)
BMJ. 2020 Oct 22;371:m3939. (PMID: 33093056)
JAMA. 2020 Aug 4;324(5):460-470. (PMID: 32492084)
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12528. (PMID: 32398379)
N Engl J Med. 2021 Feb 18;384(7):619-629. (PMID: 33232588)
Cell Rep Med. 2021 Apr 20;2(4):100252. (PMID: 33842900)
Antiviral Res. 2020 Oct;182:104868. (PMID: 32659292)
فهرسة مساهمة: Keywords: Biological sciences; Equine immunology; Immunology
تواريخ الأحداث: Date Created: 20211101 Latest Revision: 20240404
رمز التحديث: 20240404
مُعرف محوري في PubMed: PMC8539203
DOI: 10.1016/j.isci.2021.103315
PMID: 34723156
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2021.103315